Bombesin receptor antagonists

Critical Reviews in Oncology/Hematology

Volumn 24, Issue 2, 1996, Pages 117-151

  De Castiglione, Roberto ^a   Gozzini, Luigia ^b  

^a PFIZER INC   (United States)

^b Bracco SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOMBESIN ANTAGONIST; BOMBESIN DERIVATIVE; SUBSTANCE P DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER; HORMONAL THERAPY; HUMAN; NONHUMAN; REVIEW;

EID: 0030272247     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/1040-8428(96)00220-X     Document Type: Review

References (215)

1. [1] Anastasi A, Erspamer V, Bucci M. Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the European amphibian Bombina and Alytes. Experientia 27:166-167, 1971.
2. [2] Anastasi A, Erspamer V, Endean R. Amino acid composition and sequence of litorin, a bombesin-like nonapeptide occurring in methanol extracts of the skin of the Australian leptodactylid frog Litoria aurea. Experientia 31:510, 1975.
3. [3] Nakajima T, Tanimura T, Pisano JJ. Isolation and structure of a new vasoactive polypeptide. Fed Proc 29:282, 1970.
4. [4] Yasuhara T, Nakajima T, Nokihara C, Yanaihara N, Erspamer V, Falconieri Erspamer G. Two new frog skin peptides, phyllolitorins, of the bombesin-ranatensin family Phyllomedusa sauvagei. Biomed Res 4:407-412, 1983.
5. [5] McDonald TJ, Jörnvall H, Ghatei M, et al. Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. FEBS Lett 122:45-48, 1979.
6. [6] Minamino R, Kangawa K, Matsuo H. Neuromedin B: a novel bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun 114:541-548, 1983.
7. [7] Minamino N, Kangawa L, Matsuo H. Neuromedin C: a bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun 119:14-20, 1984.
8. [8] Nagalla SR, Gibson BW, Tang D, Reeve JR Jr, Spindel ER. Gastrin-releasing peptide (GRP) is not mammalian bombesin. Identification and molecular cloning of a true amphibian GRP distinct from amphibian bombesin in Bombina orientalis. J Biol Chem 267:6916-6922, 1992.
9. [9] Falconieri Erspamer G, Severini C, Erspamer V, Melchiorri P, Delle Fave G, Nakajima T. Parallel bioassay of 27 bombesin-like peptides on 9 smooth muscle preparations. Structure-activity relationships and bombesin receptor subtypes. Regul Pept 21:1-11, 1988.
10. [10] Cardona C, Rabbitts PH, Spindel ER, et al. Production of neuromedin B and neuromedin B gene expression in human lung tumor cell lines. Cancer Res 51:5205-5211, 1991.
11. [11] Spindel ER, Chin WW, Price J, Rees LH, Besser GM, Habener JF. Cloning and characterization of cDNAs encoding human gastrin-releasing peptides. Proc Natl Acad Sci USA 81:5699-5703, 1984.
12. [12] Krane IM, Naylor SL, Helin-Davis D, Chin WW, Spindel ER. Molecular cloning of cDNAs encoding the human bombesin-like peptide neuromedin B. J Biol Chem 263:13317-13332, 1988.
13. [13] Regoli D, Dion S, Rhaleb N-E, Drapeau G, Rouissi N, D'Orleans-Juste P. Receptors for neurokinins, tachykinins, and bombesin: a pharmacological study. Ann NY Acad Sci 547:158-173 1988.
14. [14] von Schrenck T, Heinz-Erian P, Moran T, Mantey SA, Gardner JD, Jensen RT. Neuromedin B receptor in esophagus: evidence for subtypes of bombesin receptor. Am J Physiol 256:G747-G758, 1989.
15. [15] Ladenheim EE, Jensen RT, Mantey SA, Mc Hugh PR, Moran TH. Receptor heterogeneity for bombesin-like peptides in the rat central nervous system. Brain Res 537:223-240, 1990.
16. [16] Lee MC, Jensen RT, Coy DH, Moody TW. Autoradiographic localization of neuromedin B binding sites in rat brain. Mol Cell Neurosci 1:161-167, 1990.
17. [17] von Schrenck T, Wang L-H, Coy DH, Villanueva ML, Mantey S, Jensen RT. Potent bombesin receptor antagonists distinguish receptor subtypes. Am J Physiol 259:G468-G473, 1990.
18. [18] Corjay MH, Dobrzanski DJ, Way JM, et al. Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J Biol Chem 266:18771-18779, 1991.
19. [19] Kilgore WR, Mantyh PW, Mantyh CR, McVey DC, Vigna SR. Bombesin/GRP-preferring and neuromedin B-preferring receptors in the rat urogenital system. Neuropeptides 24:43-52, 1993.
20. [20] Cardona C, Reeve JG, Blechen NM. Evidence for the existence of separate receptors for gastrin releasing peptide, neuromedin B and phyllolitorin in human tumour cell lines. Br J Cancer 63 (suppl 13): 14, 1991.
21. [21] Fathi Z, Corjay MH, Shapira H, et al. BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma. J Biol Chem 268:5979-5984, 1993.
22. [22] Rozengurt E. Bombesin stimulation of mitogenesis. Specific receptors, signal transduction, and early events. Am Rev Respir Dis 142:S11-S15, 1990.
23. [23] Cirillo DM, Gaudino G, Naldini L, Comoglio PM. Receptor for bombesin with associated tyrosine kinase activity. Mol Cell Biol 6:4641-4649, 1986.
24. [24] Zachary I, Gil J, Lehman W, Sinnett-Smith J, Rozengurt E. Bombesin, vasopressin, and endothelin rapidly stimulate tyrosine phosphorylation in intact Swiss 3T3 cells. Proc Natl Acad Sci USA 88:4577-4581, 1991.
25. [25] Erspamer V. Peptides of the amphibian skin active on the gut. II. Bombesin-like peptides: isolation, structure, and basic functions. In: Glass GBJ, ed. Gastrointestinal Hormones. New York: Raven Press, 1980; 343-361.
26. [26] Taché Y, Brown M. On the role of bombesin in homeostasis. Trends Neurosci 5:431-433, 1982.
27. [27] Walsh JH. Bombesin-like peptides. In: Kieger DT, Brownstein MJ, Martin JB, eds. Brain Peptides. New York: Wiley-Interscience, 1983; 941-960.
28. [28] Zachary I, Woll PJ, Rozengurt E. A role for neuropeptides in the control of cell proliferation. Dev Biol 124:295-308, 1987.
29. [29] Lebacq-Verheyden, Trepel J, Sausville EA, Battey JF. Bombesin and gastrin-releasing peptide: neuropeptides, secretogogues, and growth factors. In: Sporn MB, Roberts AB, eds. Peptide Growth Factors and Their Receptors II. New York: Springer-Verlag, 1991; 71-124.
30. [30] Broccardo C, Falconieri Erspamer G, Melchiorri P, Negri L, de Castiglione R. Relative potency of bombesin-like peptides. Br J Pharm 55:221-227, 1975.
31. [31] Rivier JE, Brown MR. Bombesin, bombesin analogues, and related peptides: effects on thermoregulation. Biochemistry 17:1766-1771, 1978.
32. [32] Moody TW, Crawley JN, Jemen RT. Pharmacology and neurochemistry of bombesin-like peptides. Peptides 3:559-563, 1982.
33. [33] Cuttitta F, Carney DN, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature (Lond) 316:823-826, 1985.
34. [34] Sunday ME, Kaplan EM, Motoyama E, Chin WW, Spindel ER. Gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease. Lab Invest 59:5-24, 1988.
35. [35] Moody TW, Korman LY. The release of bombesin-like peptides from small cell lung cancer cells. Ann NY Acad Sci 547:351-359, 1988.
36. [36] Giacchetti S, Gauvillé C, de Crémoux P, et al. Characterization, in some human breast cancer cell lines, of gastrin-releasing peptide-like receptors which are absent in normal breast epithelial cells. Int J Cancer 46:293-298, 1990.
37. [37] Pagani A, Papotti M, Sanfilippo B, Bussolati G. Expression of the gastrin-releasing peptide gene in carcinomas of the breast. Int J Cancer 47:371-375, 1991.
38. [38] Narayan S, Guo Y-S, Townsend CM Jr, Singh P. Specific binding and growth effects of bombesin-related peptides on mouse colon cancer cells in vitro. Cancer Res 50:6772-6778, 1990.
39. [39] Frucht H, Gazdar A, Park J-A, Oie H, Jensen RT. Characterization of functional receptors for gastrointestinal hormones on human colon cancer cells. Cancer Res 52:1114-1122, 1992.
40. [40] Avis FP, Maneckjee R, Cuttitta F, Nakanishi Y, Mulshine J, Avis I. The role of gastrin releasing peptide in a pancreatic tumor cell line (Capan), Proc Am Cancer Res 29:54, 1988.
41. [41] Hajri A, Balboni G, Garaud JC, Aprahamian M, Damgé C. Gastrin-releasing-peptide stimulates growth of a pancreatic acinar cell carcinoma in vitro and in vivo. Regul Pept 40:165, 1992.
42. [42] Hajri A, Koenig M, Balboni G, Damgé C. Expression of GRP receptors in normal and cancerous pancreatic cells. Regul Pept 40:165, 1992.
43. [43] Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 63:1714-1720, 1989.
44. [44] Coy DH, Taylor JE, Jiang N-Y, et al. Developing receptor antagonists of neuropeptides: the bombesin/GRP and substance P systems. In: Schwartz TW, Hilsted LM, Rehfeld JR, eds. Neuropeptides and Their Receptors. Copenhagen: Munksgaard, 1990; 376-388.
45. [45] Jensen RT, Coy DH. Progress in the development of potent bombesin receptor antagonists. Trends Pharmacol Sci 12:13-19, 1991.
46. [46] Houben H, Denef C. Bombesin receptor antagonists and their use in the evaluation of paracrine and autocrine intercellular communication. Front Horm Res 19:176-195, 1991.
47. [47] Coy DH, Jensen RT, Jiang N-Y, Lin J-T, Bogden AE. Systematic development of bombesin/gastrin-releasing peptide antagonists. J Natl Cancer Inst Monogr 13:133-139, 1992.
48. [48] Jensen RT, Jones SW, Folkers K, Gardner JD. A synthetic peptide is a bombesin receptor antagonist. Nature (Lond) 309:61-63, 1984.
49. [49] Woll PJ, Rozengurt E. A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro. Cancer Res 50:3968-3973, 1990.
50. 2+ mobilization, inositol phosphate accumulation, and clonal growth in small cell lung cancer cells. Cancer Res 51:1674-1679, 1991.
51. [51] Sethi T, Langdon S, Smyth J, Rozengurt E. Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Cancer Res (Suppl) 52:2737s-2742s, 1992.
52. [52] Takuwa N, Takuwa Y, Ohue Y, et al. Stimulation of calcium mobilization but not proliferation by bombesin and tachykinin neuropeptides in human small cell lung cancer cells. Cancer Res 50:240-244, 1990.
53. [53] Bunn PA, Dienhart DG, Chan D, Tagawa M, Jewett P. Effects of neuropeptides on human lung and breast cancer cells. J Natl Cancer Inst Monogr 13:145-151, 1992.
54. 2+-mobilizing, and mitogenic effects of endothelin and vasoactive intestinal contractor in mouse 3T3 cells. J Cell Physiol 145:88-94, 1990.
55. [55] Tan-No K, Sakurada T, Yamada T, Sakurada S, Kisara K. Spantide-induced antinociception in the opioid mechanism. Regul Pept 46:343-345, 1993.
56. [56] Bitar KG, Bowers CY, Coy DH. Effect of substance P/bombesin antagonists on the release of growth hormone by GHRP and GHRH. Biochem Biophys Res Commun 180:156-161, 1991.
57. [57] Iwatsuki K, Horiuchi A, Ren LM, Chiba S. Effects of gastrin releasing peptide (GRP) on pancreatic exocrine secretion in anaesthetized dogs. Asia Pac J Pharmacol 7:129-134, 1992.
58. [58] Patel KV, Schrey MP. Modulation of inositol lipid hydrolysis in human breast cancer by two classes of bombesin antagonists. J Mol Endocrinol 6:71-78, 1991.
59. [59] von Schrenck T, Wang L-H, Coy DH, Villanueva ML, Mantey S, Jensen RT. Potent bombesin receptor antagonists distinguish receptor subtypes. Am J Physiol 259:G468-G473, 1990.
60. [60] Coy DH, Heinz-Erian P, Jiang N-Y, et al. Progress in the development of competitive bombesin antagonists. Ann NY Acad Sci 547:150-157, 1988.
61. [61] Rusconi L, de Castiglione R, Gozzini L, et al. Bombesin receptor antagonists. 2. Analogues based on substance P antagonists. Farmaco 46:725-742, 1991.
62. [62] Cowan A, Khunawat P, Zhu XZ, Gmerek DE. Effects of bombesin on behavior. Life Sci 37:135-145, 1985.
63. 14)-bombesin: a new class of bombesin receptor antagonist. Can J Physiol Pharmacol 64 (Suppl): 175, 1986.
64. [64] Flynn FW. Fourth ventricular injection of selective bombesin receptor antagonists facilitates feeding in rats. Am J Physiol 264:R218-R221, 1993.
65. [65] Mukai H, Kawai K, Suzuki S, Yamashita K, Munekata E. Antagonism by GRP(18-27) and substance P analogues on insulin release stimulated by GRP(18-27). Peptides 11:173-175, 1990.
66. [66] de Castiglione R, Gozzini L, Mena R, et al. Bombesin receptor antagonists. 1. Analogues with deleted, inverted or substituted amino acid residues. Farmaco 45:1251-1263, 1990.
67. 6]gastrin-releasing peptide-10: an analogue with dissociated biological activities. Am J Physiol 257:E235-E240, 1989.
68. [68] Mrozinski J Jr, Coy D, Neya M, Mantey S, Jensen R. Sidechain restricted analogues. A new class of bombesin receptor antagonists. Gastroenterology 104 (Suppl): A323, 1993.
69. [69] Edwards JV, Fanger BO, Cashman EA, Eaton SR, McLean LR. Amide bond substitutions and conformational constraints applied to bombesin antagonists. In: Smith JA, Rivier JE, eds. Peptides. Chemistry and Biology. Leiden: ESCOM, 1992; 52-53.
70. [70] Spanarkel M, Martinez J, Briet C, Jensen RT, Gardner JD. Cholecytokinin-27-32-amide. A member of a new class of cholecystokinin receptor antagonists. J Biol Chem 258:6746-6749, 1983.
71. [71] Martinez J, Magous R, Lignon M-F, Laur J, Castro B. Bali J-P. Synthesis and biological activity of new peptide segments of gastrin exhibiting gastrin antagonist property. J Med Chem 27:1597-1601, 1984.
72. [72] Martinez J, Rodriguez M, Bali J-P, Laur J. Phenylethylamide derivatives of the C-terminal tetrapeptide of gastrin. Int J Peptide Protein Res 28:529-535, 1986.
73. [73] Martinez J, Rodriguez M, Ball J-M, Laur J. Phenethyl ester derivative analogues of the C-terminal tetrapeptide of gastrin as potent gastrin antagonists. J Med Chem 29:2201-2206, 1986.
74. [74] Wang L-H, Coy DH, Taylor JE, et al. Desmethionine alkylamide bombesin analogues: a new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells. Biochemistry 29:616-622, 1990.
75. [75] Wang L-H, Coy DH, Taylor JE, et al. Des-Met carboxyl terminal modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists, or agonists. J Biol Chem 265:15695-15703, 1990.
76. [76] Narayan S, Spindel ER, Rubin NH, Singh P. A potent bombesin receptor antagonist inhibits bombesin-stimulated growth of mouse colon cancer cells in vitro: absence of autocrine effects. Cell Growth Differentiation 3:111-118, 1992.
77. [77] Belvisi MG, Stretton CD, Barnes PJ. Bombesin-induced bronchoconstriction in the guinea pig: mode of action. J Pharmacol Exp Ther 258:36-41, 1991.
78. [78] Alptekin N, Yagci RV, Ertan A, et al. Comparison of prolonged in vivo inhibitory activity of several potent bombesin (BN) antagonists on BN-stimulated amylase secretion in the rat. Peptides 12:749-753, 1991.
79. [79] Buchan AMJ, Meloche M, Coy DH. Inhibition of bombesin-stimulated gastrin release from isolated human G cells by bombesin analogs. Pharmacol 41:237-245, 1990.
80. [80] Singh P, Guo Y-S, Kull FC, Leban JJ. A novel bombesin receptor antagonist (2258U89) potently inhibits bombesin evoked release of gastrointestinal hormones from rats and dogs, in vitro and in vivo. Regul Pept 40:75-86, 1992.
81. 14] bombesin analogues function as small cell lung cancer bombesin receptor antagonists. Peptides 12:145-149, 1991.
82. 6-BN(6-13)OMe on vagally induced gastrin release from perfused rat stomach. Life Sci 52:725-732, 1993.
83. [83] Varga G, Adrian TE, Coy DH, Reidelberger RD. Effect of potent bombesin receptor antagonist on release of gut hormones in rats. Regul Pept 40:267, 1992.
84. [84] Varga G, Reidelberger RD, Liehr R-M, Bussjaeger LJ, Coy DH, Solomon TE. Effects of potent bombesin antagonist on exocrine pancreatic secretion in rats. Peptides 12, 493-497, 1991.
85. 6]bombesin (6-13)methylester, a bombesin receptor antagonist, towards bombesin-induced contractions in the guinea-pig and rat isolated urinary bladder. J Auton Pharmacol 12:215-222, 1992.
86. [86] Lach E, Haddad E-B, Gies J-P. Contractile effect of bombesin on guinea pig lung in vitro: involvement of gastrin-releasing peptide-preferring receptors. Lung Cell Mol Physiol 264:L80-L86, 1993.
87. [87] Mantey S, Frucht H, Coy DH, Jensen RT. Characterization of bombesin receptors using a novel, potent, radiolabeled antagonist that distinguishes bombesin receptor subtypes. Mol Pharmacol 43:762-774, 1993.
88. [88] Coy DH, Mungan Z, Rossowski WJ, et al. Development of a potent bombesin receptor antagonist with prolonged in vivo inhibitory activity on bombesin-stimulated amylase and protein release in the rat. Peptides 13:775-781, 1992.
89. [89] Ladenheim EE, Jensen RT, Mantey SA, Taylor JA, Coy DH, Moran TH. Bombesin receptor antagonists differentiate receptor subtypes in rat brain. Eur J Pharmacol 235:121-125, 1993.
90. [90] Guard S, Watling KJ, Howson W. Structure-activity requirements of bombesin for gastrin-releasing peptide- and neuromedin B-preferring bombesin receptors in rat brain. Eur J Pharmacol 240:177-184, 1993.
91. [91] Bitar KG, Coy DH. Identification and initial characterization of a putative neuromedin B-type receptor from rat urinary bladder membranes. Eur J Pharmacol 219:117-122, 1992.
92. [92] Davis TP, Crowell S, Taylor J, et al. Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists. Peptides 13:401-407, 1992.
93. [93] Staley J, Coy DH, Jensen RT, Moody TW. Solubilization and purification of bombesin/gastrin releasing peptide receptors from human cell lines. J Mol Neurosci 4:29-40, 1993.
94. [94] Feldman RI, Wu JM, Jensen JC, Mann E. Purification and characterization of the bombesin/gastrin releasing peptide receptor from Swiss 3T3 cells. J Biol Chem 265:17364-17372, 1990.
95. [95] Kim SH, Taylor JE, Jensen RT, Coy DH, Bogden AE, Moreau J-P. C-terminal modified bombesin and litorin analogs with potent in vitro and in vivo antiproliferative activity. In: Rivier JE, Marshall GR, eds. Peptides. Chemistry, Structure and Biology. Leiden: ESCOM, 1990; 182-184.
96. [96] Thomas F, Arvelo F, Antoine E, Jacrot M, Poupon MF. Antitumoral activity of bombesin analogues on small cell lung cancer xenografts: relationship with bombesin receptor expression. Cancer Res 52:4872-4877, 1992.
97. [97] Heimbrook DC, Boyer ME, Garsky VM, et al. Elucidation of a novel gastrin releasing peptide antagonist by minimal ligand analysis. In: Tam J, Kaiser ET, eds. Synthetic Peptides: Approaches to Biological Problems. New York: Alan R Liss, 1989: 295-307.
98. [98] Märki W, Brown M, Rivier JE, Bombesin analogs: effects on thermoregulation and glucose metabolism. Peptides 2 (Suppl 2): 169-171, 1981.
99. [99] Taché Y, Märki W, Rivier J, Vale W, Brown M. Gastrin releasing peptide (GRP): central nervous system (CNS) action to inhibit gastric secretion in rats. Regul Pept 1 (Suppl 1):S112, 1980.
100. [100] Heimbrook DC, Saari WS, Balishin NL, et al. Carboxyl-terminal modification of a gastrin releasing peptide derivative generates potent antagonists. J Biol Chem 264:11258-11262, 1989.
101. [101] Coy DH, Heinz-Herian P, Jiang N-Y, et al. Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activity. J Biol Chem 263:5056-5060, 1988.
102. [102] de Castiglione R, Gozzini L, Galantino M, et al. Bombesin receptor antagonists. 3. Irreversible alkylating analogues: melphalan derivatives. Farmaco 46:743-757, 1991.
103. 3 reverses intracisternal bombesin-induced inhibition of gastric acid secretion in rats. Peptides 12:665-667, 1991.
104. [104] Rouissi N, Rhaleb N-E, Nantel F, Dion S, Drapeau G, Regoli D. Characterization of bombesin receptors in peripheral contractile organs. Br J Pharmacol 103:1141-1147, 1991.
105. [105] Karlsson S, Ahrén B. Peptide receptor antagonists in the study of insulin and glucagon secretion in mice. Eur J Pharmacol 191:457-464, 1990.
106. [106] Heimbrook DC, Saari WS, Balishin NL, et al. Gastrin releasing peptide antagonists with improved potency and stability. J Med Chem 34:2102-2107, 1991.
107. [107] Heimbrook DC, Wallen JW, Balishin NL, Friedman A, Oliff A. High-density functional gastrin releasing peptide receptors on primate cells. J Natl Cancer Inst 82:402-407, 1990.
108. [108] Heimbrook DC, Saari WS, Balishin NL, et al. Design and evaluation of novel gastrin-releasing peptide antagonists for the treatment of small cell lung cancer. In: Rivier JE, Marshall GS, eds. Peptides. Chemistry, Structure and Biology. Leiden: ESCOM, 1990; 56-59.
109. 14]bombesin and N-pivaloyl GRP(20-25) alkylamide (L 686,095-001C002) on basal and neuromedin C-stimulated PRL and GH release in pituitary cell aggregates. Peptides 12:371-374, 1991.
110. [110] Camble R, Cotton R, Dutta AS, et al. N-Isobutyryl-His-Trp-Ala-Val-D-Ala-His-Leu-NHMe (ICl 216140) a potent in vivo antagonist of bombesin/gastrin releasing peptide (BN/GRP) derived from the C-terminal sequence lacking the final methionine residue. Life Sci 45:1521-1527, 1989.
111. [111] Campbell B, Garner A, Dimaline R, Dockray GJ. Hormonal control of avian pancreas by gastrin-releasing peptide from the proventriculus. Am J Physiol 261:G16-G21, 1991.
112. [112] Cowan A, Daniel JL, Ryan RR, Wheeler-Aceto H. Pharmacological profile of ICl 216140, a novel bombesin antagonist. Eur J Pharmacol 183:235-236, 1990.
113. [113] Ryan RR, Daniel JL, Cowan A. Two bombesin analogues discriminate between neuromedin B- and bombesin-induced calcium flux in a lung cancer cell line. Peptides 14:1231-1235, 1993.
114. 24] GRP(20-26)-heptapeptide. Modifications leading to potent analogues with prolonged duration of action. Drug Des Deliv 6:255-271, 1990.
115. [115] Best JR, Byrne P, Cotton R, et al. Antagonists of bombesin/gastrin-releasing peptide based on GRP(21-26)-heptapeptide. Effects of N- and C-terminal modifications. Drug Des Deliv 5:267-280, 1990.
116. [116] Martinez J, Bali J-P, Rodriguez M, Castro B, Magous R, Laur J. Synthesis and biological activities of some pseudo-peptide analogues of tetragastrin: the importance of the peptide backbone. J Med Chem 28:1874-1879, 1985.
117. 1H-NMR techniques. Eur J Biochem 168:193-199, 1987.
118. [118] Erne D, Schwyzer R. Membrane structure of bombesin studied by infrared spectroscopy. Prediction of membrane interactions of gastrin-releasing peptide, neuromedin B, and neuromedin C. Biochemistry 26:6316-6319, 1987.
119. 14]bombesin(6-14). Biopolymers 31:1397-1408, 1991.
120. [120] Malikayil JA, Edwards JV, McLean LR. Micelle-bound conformations of a bombesin/gastrin releasing peptide receptor agonist and an antagonist by two-dimensional NMR and restrained molecular dynamics. Biochemistry 31:7043-7049, 1992.
121. [121] Coy DH, Jiang N-Y, Kim SH, et al. Covalently cyclized agonist and antagonist analogues of bombesin and related peptides. J Biol Chem 266:16441-16447, 1991.
122. [122] Kull FC Jr, Leban JJ, Landavazo A, Stewart KD, Stockstill B, McDermed JD. Conveyance of partial agonism/antagonism to bombesin/gastrin-releasing peptide analogues on Swiss 3T3 cells by a carboxyl-terminal leucine insertion. J Biol Chem 267:21132-21138, 1992.
123. 14]bombestn is a specific bombesin receptor antagonist in Swiss 3T3 cells. Biochem Biophys Res Commun 155:359-365, 1988.
124. 2O) amide bond surrogate. Biochem Biophys Res Commun 165:114-117, 1989.
125. [125] Woll PJ, Rozengurt E. Two classes of antagonist interact with receptors for the mitogenic neuropeptides bombesin, bradykinin, and vasopressin. Growth Factors 1:75-83, 1988.
126. [126] Millar JBA, Rozengurt E. Arachidonic acid release by bombesin. A novel postreceptor target for heterologous mitogenic desensitization. J Biol Chem 265:19973-19979, 1990.
127. r = 80 000 protein kinase C substrate in permeabilizes 3T3 cells. Effect of guanine nucleotides. J Biol Chem 263:19188-19194, 1988.
128. [128] Brooks SF, Herget T, Broad S, Rozengurt E. The expression of 80 K/MARCKs, a major substrate of protein kinase C (PKC). is down-regulated through both PKC-dependent and -independent pathways. Effect of bombesin, platelet-derived growth factor, and cAMP. J Biol Chem 267:14212-14218, 1992.
129. [129] Millar JBA, Rozengurt E. Chronic desensitization to bombesin by progressive down-regulation of bombesin receptors in Swiss 3T3 cells. Distinction from acute desensitization. J Biol Chem 265:12052-12058, 1990.
130. [130] Trepel JB, Moyer JD, Cuttitta F, et al. A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line. Biochem Biophys Res Commun 156:1383-1389, 1988.
131. [131] Mahamoud S, Palaszynski E, Fiskum G, Coy DH, Moody TW. Small cell lung cancer bombesin receptors are antagonized by reduced peptide bond analogues. Life Sci 44:367-373, 1989.
132. 13,14] bombesin analogues inhibit growth of small cell lung cancer in vitro and in vivo. Cancer Res 51:1798-1802, 1991.
133. [133] Sausville EA, Trepel JB, Moyer JD. Inhibitors of bombesin-stimulated intracellular signals: interruption of an autocrine pathway as a therapeutic strategy in small cell lung carcinoma. In: Ragaz J, et al., eds. Effects of Therapy on Biology and Kinetics of the Residual Tumor, Part A: Pre-Clinical Aspects. New York: Wiley-Liss, 1990; 193-207.
134. [134] Ciomei M, Pastori W, Pastori A, de Castiglione R, Gozzini L, Corradi F. In vitro and in vivo activity of alkylating bombesin receptor antagonists on small cell lung carcinoma. Anticancer Res 13:75-80, 1993.
135. 14]-bombesin as a specific bombesin receptor antagonist on isolated smooth muscle cells. J Pharmacol Exp Ther 251:713-717, 1989.
136. 14)-bombesm. Scand J Gastroenterol 25:89-96, 1990.
137. [137] Rossowski WJ, Murphy WA, Jiang N-J, Yeginsu O. Effects of a novel antagonist analogue on bombesin-stimulated gastric acid secretion and growth hormone release in the pentobarbital-anesthetized rat. Scand J Gastroenterol 24:121-128, 1989.
138. [138] Schubert ML, Hightower J, Coy DH, Makhlouf GM. Regulation of acid secretion by bombesin/GRP neurons of the gastric fundus. Am J Physiol 260:G156-G160, 1991.
139. [139] Schubert ML, Coy DH, Makhlouf GM. Peptone stimulates gastrin secretion from the stomach by activating bombesin/GRP and cholinergic neurons. Am J Physiol 262:G685-G689, 1992.
140. 13]bombesin fails to suppress nutrient-induced CCK release from rat duodenojejunum. Peptides 11:255-258, 1990.
141. [141] Campos RV, Buchan AMJ, Pederson RA, McIntosh CHS, Coy DH. Inhibition of bombesin-stimulated gastrin release from isolated canine G cells by bombesin antagonists. Can J Pharmacol 67:1520-1524, 1989.
142. [142] Tang K-C, Pan J-T. Stimulatory effects of bombesin-like peptides on suprachiasmatic neurons in brain slices. Brain Res 614:125-130, 1993.
143. [143] Houben H, Denef C, Vranckx C. Stimulation of growth hormone release and prolactin release from rat pituitary cell aggregates by bombesin- and ranatensin-like peptides is potentiated by estradiol, 5α-dihydrotestosterone, and dexamethasone. Endocrinology 126:2257-2266, 1990.
144. [144] Feldman EL, Randolph AE. Peptides stimulate phospho-inositide hydrolysis in human retinal pigment epithelium. Invest Ophthalmol Visual Sci 34:431-437, 1993.
145. [145] Merali Z, Moody TW, Coy DH. Blockade of brain bombesin/GRP receptors increases food intake in satiated rats. Am J Physiol 264:R1031-R1034, 1993.
146. [146] Motamedi F, Rashidi-Pour A, Zarrindast MR, Badavi M. Bombesin-induced anorexia requires central bombesin receptor activation: independence from interaction with central catecholaminergic systems. Psychopharmacol 110:193-197, 1993.
147. [147] Bado A, Moizo L, Laigneau J-P, Gauthier M, Dubrasquet M, Lewin MJM. Possible mediation by luminal somatostatin of bombesin-induced satiety in the cat. Am J Physiol 263:R84-R88, 1992.
148. [148] Babcock AM, Baker DA, Moody TW. Bombesin-induced hypothermia: a dose-response and receptor antagonist study. Pharmacol Biochem Behav 43:957-960, 1992.
149. 14-bombesin, a proposed competitive antagonist of bombesin. FASEB J 2:A784, 1988.
150. 13]-bombesin in frog peptic cells. Biochem Biophys Res Commun 157:1154-1158, 1988.
151. [151] Coy DH, Taylor JE, Jiang N-Y, et al. Short-chain pseudo-peptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity. J Biol Chem 264:14691-14697, 1989.
152. 10]neuromedin C antagonizes neuromedin C-stimulated amylase release by acini isolated from the rat pancreas. Pancreas 5:408-414, 1990.
153. [153] Coy D, Wang L-H, Jiang N-Y, Jensen R. Short chain bombesin pseudopeptides with potent bombesin receptor antagonist activity in rat and guinea pig pancreatic acinar cells. Eur J Pharmacol 190:31-38, 1990.
154. 14]BN(6-14) on adult behavior and sensitivity to BN. Peptides 14:845-848, 1993.
155. [155] Laferrère B, Leroy F, Bonhomme G, Le Gall A, Basdevant A, Guy-Grand B. Effects of bombesin, of a new bombesin agonist (BIM187) and a new antagonist (BIM189) on food intake in rats, in relation to cholecystokinin. Eur J Pharmacol 215:23-28, 1992.
156. [156] Radulovic S, Cai R-Z, Serfozo P, et al. Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terrninal D-Trp or D-Tpi. Int J Pept Protein Res 38:593-600, 1991.
157. [157] Cai R-Z, Radulovic S, Pinski J, et al. Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi. Peptides 13:267-271, 1992.
158. [158] Jaworek J, Konturek PK, Konturek SJ, Cai R-Z, Serially AV. Actions of novel bombesin receptor antagonists on pancreatic secretion in rats. Eur J Pharmacol 214:239-245, 1992.
159. [159] Konturek SJ, Dembinski A, Warzecha Z, et al. Antagonism of receptors for bombesin, gastrin and cholecystokinin in pancreatic secretion and growth. Digestion 48:89-97, 1991.
160. [160] Konturek SJ, Bilski J, Hladij M, Krzyzek E, Cai R-Z, Schally AV. Role of cholecystokinin, gastrin and gastrin-releasing peptide in the regulation of pancreatic secretion in cats. Digestion 49:97-105, 1991.
161. [161] Pinski J, Yano T, Rekasi Z, Cai R-Z, Radulovic S, Schally AV. High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels: comparison of different routes of administration. Regul Pept 41:185-193, 1992.
162. [162] Pinski J, Yano T, Groot K, Cai R-Z, Radulovic S, Schally AV. Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats. Am J Physiol 263:E712-E717, 1992.
163. [163] Pinski J, Yano T, Schally AV. Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats. Neuroendocrinol 56:831-837, 1992.
164. [164] Szepeshazi K, Schaily AV, Cai R-Z, Radulovic S, Milovanovic S, Szoke B. Inhibitory effects of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters. Cancer Res 51:5980-5986, 1991.
165. [165] Liebow C, Lee MT, Krebs L, Schally AV. Bombesin may stimulate growth through up-regulation of EGF receptors. Pancreas 7:746, 1992.
166. [166] Szepeshazi K, Schally AV, Groot K, Halmos G. Effect of bombesin, gastrin-releasing peptide (GRP) (14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters. Int J Cancer 54:282-289, 1993.
167. [167] Radulovic S, Comaru-Schally AM, Milovanovic S, Schally AV. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa human pancreatic cancer xenografts in nude mice. Pancreas 8:88-97, 1993.
168. [168] Radulovic SS, Milovanovic SR, Cai R-Z, Schally AV. The binding of bombesin and somatostatin and their analogs to human colon cancers. Proc Soc Exp Biol Med 200:394-401, 1992.
169. [169] Radulovic S, Miller G, Schally AV. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Cancer Res 51:6006-6009, 1991.
170. 6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160. Prostate 20:269-280, 1992.
171. [171] Pinski J, Halmos G, Szepeshazi K, Schally AV. Antagonists of bombesin/gastrin-releasing peptide as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Cancer 72:3263-3270, 1993.
172. [172] Pinski J, Schally AV, Halmos G, Szepeshazi K. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. Int J Cancer 55:963-967, 1993.
173. [173] Pinski J, Halmos G, Schally AV. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Cancer Lett 71:189-196, 1993.
174. [174] Yano T, Pinski J, Groot K, Schally AV. Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res 52:4545-4547, 1992.
175. [175] Szepeshazi K, Schally AV, Halmos G, Groot K, Radulovic S. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095. J Natl Cancer Inst 24:1915-1922, 1992.
176. [176] Libow C, Crean DH, Schally AV, Mang TS. Peptide analogues alter the progression of premalignant lesions, as measured by Photofrin fluorescence. Proc Natl Acad Sci USA 90:1897-1901, 1993.
177. 2 C terminus. Proc Natl Acad Sci USA 90:1922-1926, 1993.
178. [178] Mokotoff M, Ren K, Wong LK, LeFever AV, Lee PC. Synthesis and biological evaluation of novel potent antagonists of the bombesin/gastrin releasing peptide receptor. J Med Chem 35:4696-4703, 1992.
179. [179] Boryscwicz R, Ren KJ, Mokotoff M, Lee PC. Direct effect of bombesin on pancreatic and gastric growth in suckling rats. Regul Pept 41:157-169, 1992.
180. [180] Gawlak SL, Kiener PA, Braslawsky GR, Greenfield RS. Homodimeric forms of bombesin act as potent antagonists of bombesin on Swiss 3T3 cells. Growth Factors 5:159-170, 1991.
181. [181] de Castiglione R, Gozzini L, Galantine M, et al. Bombesin receptor antagonists. 5. New irreversible alkylating analogues. Farmaco 47:855-867, 1992.
182. [182] Lucietto P-L, de Castiglione R, Gozzini L, Ciomei M. Bombesin receptor antagonists. 4, Chloromethylketone and chloroethylnitrosourea derivatives. Farmaco 46:1111-1120, 1991.
183. [183] Zachary I, Rozengurt E. High-affinity receptors for peptide of the bombesin family in Swiss 3T3 cells. Proc Natl Acad Sci USA 82:7616-7620, 1985.
184. [184] Kris RM, Hazan R, Villines J, Moody TW, Schlessinger J. Identification of the bombesin receptor on murine and human cells by cross-linking experiments. J Biol Chem 262:11215-11220, 1987.
185. [185] Layton JE, Scanlon DB, Soveny C, Morstyn G. Effects of bombesin antagonists on the growth of small cell lung cancer cells in vitro. Cancer Res 48:4783-4789, 1988.
186. [186] Fanger BO, Wade AC. Somatostatin competes with the central portion of gastrin-releasing peptide for binding to a 120 kDa protein. Neurochem Int 18:185-189, 1991.
187. [187] Terenius L. Somatostatin and ACTH are peptides with partial antagonist-like selectivity for opiate receptor. Eur J Pharmacol 38:211-213, 1976.
188. [188] Rezek M, Havlicedk V, Leybin L, La Bella FS, Friesen H. Opiate-like naloxone-reversible actions of somatostatin given intracerebrally. Can J Pharmacol 56:227-231, 1978.
189. [189] Gulya K, Pelton JT, Hruby VJ, Yamamura HI. Cyclic somatostatin octapeptide analogues with high affinity and selectivity towards mu opioid receptors. Life Sci 38:2225-2229, 1986.
190. [190] Walker JM, Bowen WD, Atkins ST, Hemstreet MK, Coy DH. Mu-opiate binding and morphine antagonism by octapeptide analogs of somatostatin. Peptides 8:869-875, 1987.
191. [191] Orbuch M, Taylor JE, Coy DH, et al. Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues. Mol Pharmacol 44:841-850, 1993.
192. [192] Valentine JJ, Nakanishi S, Hageman DL, Snider RM, Spencer RW, Vinick FJ. CP-70,030 and CP-75,998: the first non-peptide antagonists of bombesin and gastrin releasing peptide. Biorg Med Chem Lett 2:333-338, 1992.
193. 1) receptor. Science 251:435-439, 1991.
194. [194] Carney DN, Gazdar AF, Bepler G. et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 45:2913-2923, 1985.
195. [195] Carney DN, Cuttitta F, Moody TW, Minna JD. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res 47:821-825, 1987.
196. [196] Kado-Fong H, Malfroy B. Effects of bombesin on human small cell lung cancer cells: evidence for a subset of bombesin non-responsive cell lines. J Cell Biochem 40:431-437, 1989.
197. [197] Bepler G, Rotsch M, Jaques G, Haeder M, Heymanns J, Hartogh G, Kiefer P, Havemann K. Peptides and growth factors in small cell lung cancer: production, binding sites, and growth effects. J Cancer Res Clin Oncol 114:235-244, 1988.
198. [198] Giaccone G, Battey J, Gazdar AF, Oie H, Draoui M, Moody TW. Neuromedin B is present in lung cancer cell lines. Cancer Res 52:2732s-2736s, 1992.
199. [199] Alexander RW, Upp JR Jr, Poston GI, Townsend CM Jr, Singh P, Thompson JC. Bombesin inhibits growth of human pancreatic adenocarcinoma in nude mice. Pancreas 3:297-302, 1988.
200. [200] Meijers M, Van Garderen-Hoetmer A, Earners CBHW, Rovati LC, Jensen JBMJ, Woutersen RA. Effects of bombesin on the development of N-nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters. Cancer Lett 59:45-50, 1991.
201. [201] Battey J, Wada E. Two distinct receptor subtypes for mammalian-like peptides. Trends Neurosci 14:524-528, 1991.
202. [202] Moody TW, Staley J, Zia F, Coy DH, Jensen RT. Neuromedin B binds with high affinity, elevates cytosolic calcium and stimulates the growth of small-cell lung cancer cell lines. J Pharmacol Exp Ther 263:311-317, 1992.
203. [203] Giladi E, Nagalla SR, Spindel ER. Molecular cloning and characterization of receptors for the mammalian bombesin-like peptides. J Mol Endocrinol 4 (1):41-54, 1993.
204. [204] Shapira H, Wada E, Jensen R, Battey J. Distinguishing bombesin receptor subtypes. In: Conn PM, ed. Methods in Neurosciences. New York: Academic Press, 1993; 13:220-237.
205. [205] Viallet J, Minna JD. Gastrin-releasing peptide (GRP, mammalian bombesin) in the pathogenesis of lung cancer. Prog Growth Factor Res 1:89-97, 1989.
206. [206] Moody TW, Cuttitta F. Growth factor and peptide receptors in small cell lung cancer. Life Sci 52:1161-1173, 1993.
207. [207] Korman LY, Carney DN, Citron ML, Moody TW. Secretin/vasoactive intestinal peptide-stimulated secretion of bombesin/gastrin releasing peptide from human small cell carcinoma of the lung. Cancer Res 46:1214-1218, 1986.
208. [208] Moody TW, Zia F, Makhejia A. Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells. Peptides 14:241-246, 1993.
209. [209] Maruno K, Said SI. Small-cell lung carcinoma: inhibition of proliferation by vasoactive intestinal peptide and helodermin and enhancement of inhibition by anti-bonibesin antibody. Life Sci 52:PL267-PL271, 1993.
210. [210] Woll PJ, Rozengurt E, Neuropeptides as growth regulators. Br Med Bull 45:492-505, 1989.
211. [211] Mukai H, Munekata E, Higashijima T. G protein antagonists. A novel hydrophobic peptide compete with receptor for G protein binding. J Biol Chem 267:16237-16243, 1992.
212. [212] Reubi JC, Waser B, Sheppard M, Macaulay V. Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF-receptors. Int J Cancer 45:269-274, 1990.
213. [213] Sagman U, Mullen B, Kovacs K, Kerbel R, Ginsberg R, Reubi J-C. Identification of somatostatin receptors in human small cell lung carcinoma. Cancer 66:2129-2133, 1990.
214. [214] Rehfeld JF, Bardrum L, Hilsted L. Gastrin in human bronchogenic carcinoma: constant expression but variable processing of progastrin. Cancer Res 49:2840-2843, 1989.
215. [215] Geijer T, Folkesson R, Rehfeld JF, Monstein H-J. Expression of cholecystokinin gene in a human (small-cell) lung carcinoma cell line. FEBS Lett 270:30-32, 1990.